Description

Meridia® 15 mg (chlorhydrate de sibutramine monohydraté)

Marque : Bariatrics (Abbott)
Catégorie : Centrally acting monoamine-reuptake modulator (SNRI) – Research chemical
Contenu : 30 capsules · 15 mg sibutramine HCl monohydrate per capsule
Prix : €29
Fabriqué en : L'Europe
Research Notice: FOR RESEARCH USE ONLY. Not for human or veterinary use.

🧪 Aperçu du produit

Meridia® 15 mg contains sibutramine hydrochloride monohydrate, a centrally acting
serotonin–norepinephrine reuptake inhibitor (SNRI) historically indicated for weight management
until its withdrawal following the SCOUT cardiovascular-outcomes trial.
It is now used exclusively as a laboratory/analytical reference compound for studies on
monoamine signaling, appetite regulation, toxicology, and forensic method development.

Sibutramine increases synaptic concentrations of serotonin (5-HT) et
norepinephrine (NE) by blocking their reuptake transporters. Its active metabolites
(M1/M2) are chiefly responsible for appetite-suppression pathways and sympathetic activation.

✅ Principaux résultats de la recherche

Monoamine reuptake inhibition:
Blocks SERT et NET (± DAT) → ↑ 5-HT/NE levels → enhanced satiety signaling.
Documented extensively in DrugBank and PubChem entries.

Historical pharmacotherapy:
Originally approved for obesity management; later withdrawn (EU/US, 2010) due to increased risk of
non-fatal MI and stroke in high-risk cardiovascular patients (SCOUT trial – NEJM).

Anti-doping relevance:
Classified under WADA Stimulants (in-competition). Athletes must confirm status via Global DRO.

Laboratory value:
Used in metabolic, toxicological, chromatographic, and receptor-transporter profiling workflows.

🧬 Mécanisme d'action (simplifié)

Sibutramine is metabolized into two active metabolites (M1 & M2) which:

Block serotonin (SERT) et norepinephrine (NET) transporters
Increase synaptic monoamines → enhanced satiety and reduced caloric intake
Produce mild sympathetic activation → increased HR/BP in clinical history

This profile supports its use in monoamine and appetite-regulation research models.

📊 Scientific Data Table

Champ d'application	Données
Nom chimique	Sibutramine hydrochloride monohydrate
Molecular Formula	C₁₇H₂₉Cl₂NO (monohydrate salt, PubChem)
Poids moléculaire	~334.3 g/mol (monohydrate)
Synonymes	Meridia; Reductil; Sibutramine HCl; Sibutramine HCl Monohydrate
Numéro CAS	125494-59-9 (monohydrate); 84485-00-7 (base)
PubChem CID	64765 (monohydrate); 5210 (base)
Pharmacology	SNRI (± DAT) → appetite/satiety modulation via monoamine elevation
Doping Status	Stimulants – Prohibited in competition (WADA)

📚 Research Background

SCOUT Trial (NEJM): Increased non-fatal MI and stroke in high-risk cardiovascular groups → regulatory withdrawal.
Mechanistic relevance: Appetite suppression linked to SERT/NET inhibition and downstream hypothalamic pathways.
Toxicology interest: Cardiovascular, serotonergic, and sympathomimetic components evaluated in controlled studies.

⚠️ Documented Risks (Historical Medicinal Use)

↑ Heart rate and blood pressure
Increased risk of non-fatal MI and stroke (SCOUT)
Insomnia, dry mouth, headache, constipation
Possible serotonin-related interactions (SSRIs/MAOIs)

🧯 Compliance & Legal Status

Regulation: Suspended/withdrawn in EU/US (2010). Not marketed as a medicinal product on this site.
Research-only: Supplied strictly for laboratory/analytical use.
Sport: Listed under WADA Stimulants (Prohibited In-Competition).
Researchers and athletes must verify local regulations and anti-doping rules.

📌 Important Notice

This compound is for laboratory research only.
Not for human consumption, therapeutic use, or veterinary application.
Users are responsible for compliance with local laws, regulations, and safety protocols.

Rated 5 out of 5
Basé sur les commentaires de 0

Classé 5 sur 5